ID   A2058-RFP/H2B-GFP
AC   CVCL_XH73
SY   A2058(RFP/H2B-GFP)
DR   cancercelllines; CVCL_XH73
DR   Wikidata; Q93311453
RX   PubMed=27521448;
CC   Population: Caucasian.
CC   Characteristics: The H2B-eGFP fusion construct is under the control of the pPGK promoter and localizes to the nucleus.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 4761; H2BC11 (with p.Gly26Asp and p.Ile119Val and fused in frame with eGFP).
CC   Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP).
CC   Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1059 ! A2058
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 9
//
RX   PubMed=27521448; DOI=10.1158/1078-0432.CCR-16-1327;
RA   Osswald M., Blaes J., Liao Y.-X., Solecki G., Gommel M., Berghoff A.S.,
RA   Salphati L., Wallin J.J., Phillips H.S., Wick W., Winkler F.;
RT   "Impact of blood-brain barrier integrity on tumor growth and therapy
RT   response in brain metastases.";
RL   Clin. Cancer Res. 22:6078-6087(2016).
//